Full-Time

Medical Science Liaison

Dermatology/Autoimmune Disorders

Posted on 12/13/2025

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$100.5k - $172.7k/yr

+ Bonus + Company Vehicle

Alberta, Canada + 1 more

More locations: Saskatchewan, Canada

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Advanced degree in health sciences (PhD, MD, Pharm D) with 2-3 years of relevant clinical or therapeutic experience in dermatology.
  • OR MSc in health care/professional designation (BScN, PT, RD etc.) considered if 5 or more years of relevant clinical experience in dermatology
  • OR previous Medical Science Liaison experience and sound knowledge of the pharmaceutical industry
Responsibilities
  • The MSL will serve as a scientific resource for Canadian experts in the field of Dermatology and related autoimmune disorders. The MSL is responsible for responding to requests for in depth, cutting edge scientific information from the medical community in the autoimmune field including the latest scientific literature, the latest research from major scientific conferences, updates on Lilly’s educational activities and Lilly’s pipeline research activities.
  • The MSL will also gather feedback and insight from Scientific Experts and Thought Leaders to better inform Lilly’s research and overall strategic direction. By facilitating scientific exchange between the academic community and Lilly, the MSL has the opportunity to shape the future of healthcare with information that addresses important clinical and scientific questions.
  • The MSL has responsibility to ensure that activities are compliant with all applicable guidelines, Rules and Regulations for Conducting Research, Rx and D Code of Conduct, the Eli Lilly Canada Policy on the Promotion of Pharmaceutical Products and Ethical Interactions with Health Care Providers, and other prevailing regulations/codes that may pertain to their work in the future.
  • Develop and maintain mutually beneficial, peer-to-peer relationships with the scientific community
  • The MSL will spend a significant amount of their time on customer-facing activities to develop relationships with external customers including scientific experts, researchers, educators and clinical investigators. The MSL will serve as a major representative of Lilly for these health care professionals, providing deep and advanced disease state and product information as well as facilitating the work of the scientific expert when it aligns with Lilly's mission. An important aspect of this work will be to connect thought leaders and scientific experts with other Lilly resources (e.g., Discovery, Real World Evidence Scientists, Clinical Research Physicians and Global/Canadian External Research & Development).
  • Effectively communicate with Scientific Experts and Thought Leaders with up to date scientific knowledge and provide services that meet their needs.
  • The MSL will be considered a reliable, trusted resource of accurate, up-to-date medical and scientific knowledge requested and desired by their customers. They will respond in a timely way to personal or electronic inquiries with any available information which may include reprints or posters, medical letters, literature citations, access to internal and external experts, slides and other teaching-related material.
  • Continually enhance scientific knowledge
  • The MSL is required to maintain technical expertise within a therapeutic area to engage in scientific discussions with scientific experts. The MSL will be expected to engage in continuous learning within the therapeutic area they represent. They will attend appropriate scientific meetings, conduct routine literature searches and will be expected to communicate regularly with each other to assure that the entire group benefits from individual learning whenever it is relevant.
  • Support the affiliate medical business objectives and cross functional partner
  • The MSL will be responsible for interfacing the scientific expert and Lilly resources/internal business partners such as Clinical Research Physicians, Medical Information Associates, Medical Education, Corporate Affairs, and Marketing as requested by the expert. They will also report the clinical insights and unanswered customer questions they have received from the scientific experts to the medical and brand teams. The MSL job entails not only scientific and customer expertise, but also requires the ability to understand and effectively utilize approved resources to fulfill administrative, procedural, and legal requirements in order to address the customer needs and support internal Lilly business.
Desired Qualifications
  • Intellectual curiosity and intelligence about the field of immunology/autoimmune disorders
  • Ability to critically appraise scientific information / literature
  • Strong presentation skills including the ability to comprehend large amounts of scientific content which is then communicated in a clear, concise fashion
  • Demonstrated ability to build strong/collaborative peer-to-peer relationships with external customers
  • Familiarity with the academic community and medical research
  • Significant direct experience in servicing customer needs for complex information
  • Experience in professional networking with positive mutually beneficial outcome
  • Strong teamwork and interpersonal skills including an ability to work effectively with internal colleagues and cross-functional team member
  • Strong project management skills with an ability to work within teams to prioritize key projects and medical tactics
  • Previous Medical Science Liaison experience
  • Significant clinical or research work in the areas of autoimmune diseases including Dermatology
  • Coverage territory: Alberta/Saskatchewan

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • Orforglipron can convert injectable obesity patients to a once-daily oral maintenance therapy.
  • LimmaTech adds vaccine programs against Staphylococcus aureus, gonorrhea, and chlamydia.
  • The EBV vaccine acquisition broadens Lilly into high-value infectious disease prevention.

What critics are saying

  • Orforglipron can cannibalize Zepbound and slow retention in Lilly's injectable franchise.
  • Obesity rivals are crowding the market, compressing Lilly's lead on efficacy and access.
  • Preclinical and Phase 1 vaccine deals can fail, destroying capital before commercialization.

What makes Lilly USA unique

  • Lilly combines dominant GLP-1 commercialization with aggressive pipeline expansion into infectious disease.
  • Its $4.5 billion Indiana expansion secures manufacturing capacity for surging obesity demand.
  • TuneLab extends Lilly-trained AI models into external biotech workflows, deepening ecosystem reach.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE